Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.44 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948034 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29424533 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL31470993 | 0.88 | CASP3 (0.63) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL120580 | 0.88 | CASP3 (0.63) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL30604630 | 0.88 | CASP3 (0.63) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL31450834 | 0.88 | KMT2A (0.48) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL31450833 | 0.87 | CASP3 (0.48) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL31451006 | 0.87 | CASP3 (0.48) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL15873350 | 0.87 | CASP3 (0.48) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL15873353 | 0.87 | CASP3 (0.48) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50643-E1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4556469-A1 | BENZAMIDE COMPOUNDS | Recurium IP Holdings, LLC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3740487-B1 | BENZAMIDE COMPOUNDS AS BCI INHIBITORS FOR THE TREATMENT OF HIV | RECURIUM IP HOLDINGS LLC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240180899-A1 | BENZAMIDE COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2024-06-06 | — | — | US | disclosed |
| US-11813259-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813260-B1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-11590126-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220273666-A1 | NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR | RECURIUM IP HOLDINGS, LLC | 2022-09-01 | — | — | US | disclosed |
| US-20220265834-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2022-08-25 | — | — | US | disclosed |
| US-20220226314-A1 | BENZAMIDE COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2022-07-21 | — | — | US | disclosed |
| US-8624027-B2 | Combination therapy for treating cancer and diagnostic assays for use therein | ABBVIE INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2506853-A1 | COMBINATION THERAPY FOR TREATING CANCER AND DIAGNOSTIC ASSAYS FOR USE THEREIN | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011068863-A1 | COMBINATION THERAPY FOR TREATING CANCER AND DIAGNOSTIC ASSAYS FOR USE THEREIN | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| US-7906505-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100249133-A1 | APOPTOSIS PROMOTERS | Abbott Laboraoties | 2010-09-30 | — | — | US | disclosed |
| US-20100227838-A1 | Combination Therapy for Treating Cancer and Diagnostic Assays for Use Therein | ABBOTT LABORATORIES (US) | 2010-09-09 | — | — | US | disclosed |
| US-7709467-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080287419-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-11-20 | — | — | US | disclosed |
| US-7390799-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070027135-A1 | N-acylsulfonamides; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide | ABBVIE INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813259-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | CASP3 359/4885KMT2A 1132/4885MDM4 932/4885 |
| US-11813260-B1 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | CASP3 359/4885KMT2A 1132/4885MDM4 932/4885 |
| US-20220265834-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | CASP3 67/4885KMT2A 2119/4885MDM4 1380/4885 |
| US-11590126-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | CASP3 359/4885KMT2A 1132/4885MDM4 932/4885 |
| US-20220273666-A1 | NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR | BCL2, BCL2L2, BCL2L1 | CASP3 47/4885KMT2A 1466/4885MDM4 2529/4885 |
| US-20220226314-A1 | BENZAMIDE COMPOUNDS | MKI67, TMBIM6, HDAC1 | CASP3 359/4885KMT2A 1132/4885MDM4 932/4885 |
| US-20080287419-A1 | APOPTOSIS PROMOTERS | BAX, API5, BCL2 | CASP3 21/4885KMT2A 3898/4885MDM4 1391/4885 |
| US-20070027135-A1 | N-acylsulfonamides; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide | BAX, BCL2L1, BCL2A1 | CASP3 19/4885KMT2A 2466/4885MDM4 1467/4885 |
| US-20240180899-A1 | BENZAMIDE COMPOUNDS | MKI67, TMBIM6, HDAC1 | CASP3 359/4885KMT2A 1132/4885MDM4 932/4885 |
| US-20100249133-A1 | APOPTOSIS PROMOTERS | BAX, API5, BCL2 | CASP3 21/4885KMT2A 3898/4885MDM4 1391/4885 |
| US-20100227838-A1 | Combination Therapy for Treating Cancer and Diagnostic Assays for Use Therein | FOLH1, TP53, NTPCR | CASP3 1295/4885KMT2A 3377/4885MDM4 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.